Evotec
Evotec is a leader in protein homeostasis, combining precision medicine with innovative TPD platforms. Building on the collaboration with Bristol Myers Squibb to discover Cereblon-based molecular glues, Evotec’s internal R&D advances next-generation TPD approaches, including a first-in-class molecular glue library based on a novel E3 ligase, a high-throughput glue discovery engine, autophagy-targeting degraders and DACs. Powered by world-leading PanOmics, Evotec is building a proprietary portfolio of degrader programs against diseases with a high unmet medical need.
